{
  "ticker": "AVBP",
  "company_name": "ArriVent BioPharma, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT07010419",
      "title": "A Study to Assess the Efficacy and Safety of Firmonertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB - IIIB NSCLC With Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations, Following Complete Surgical Resection With or Without Adjuvant Chemotherapy\uff08FIRMOST\uff09",
      "status": "RECRUITING",
      "phase": "PHASE3",
      "condition": "NSCLC, Adjuvant Treatment",
      "start_date": "2025-05-28",
      "completion_date": "2032-04-30",
      "enrollment": 0,
      "sponsor": "Allist Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT05364073",
      "title": "Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE1",
      "condition": "Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, HER2 Exon 20 Mutations, EGFR Exon 20 Mutations, EGFR Uncommon Mutations, Including G719X and S768I",
      "start_date": "2022-06-30",
      "completion_date": "2025-12",
      "enrollment": 0,
      "sponsor": "ArriVent BioPharma, Inc."
    },
    {
      "nct_id": "NCT05607550",
      "title": "Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "condition": "Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, EGFR Exon 20 Mutations",
      "start_date": "2023-06-01",
      "completion_date": "2028-02-15",
      "enrollment": 0,
      "sponsor": "ArriVent BioPharma, Inc."
    },
    {
      "nct_id": "NCT07185997",
      "title": "Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations",
      "status": "RECRUITING",
      "phase": "PHASE3",
      "condition": "Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer, EGFR P-Loop and Alpha C-Helix Compressing, EGFR PACC, EGFR Uncommon Mutations",
      "start_date": "2025-12",
      "completion_date": "2030-12",
      "enrollment": 0,
      "sponsor": "ArriVent BioPharma, Inc."
    },
    {
      "nct_id": "NCT07066657",
      "title": "A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer",
      "start_date": "2025-07-25",
      "completion_date": "2030-12",
      "enrollment": 0,
      "sponsor": "Lepu Biopharma Co., Ltd."
    }
  ],
  "summary": {
    "total_trials": 5,
    "by_phase": {
      "PHASE3": 3,
      "PHASE1": 2
    },
    "by_status": {
      "RECRUITING": 3,
      "ACTIVE_NOT_RECRUITING": 2
    },
    "active_trials": 5,
    "completed_trials": 0,
    "conditions": [
      "Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer",
      "Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, EGFR Exon 20 Mutations",
      "NSCLC, Adjuvant Treatment",
      "Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, HER2 Exon 20 Mutations, EGFR Exon 20 Mutations, EGFR Uncommon Mutations, Including G719X and S768I",
      "Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer, EGFR P-Loop and Alpha C-Helix Compressing, EGFR PACC, EGFR Uncommon Mutations"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:16:48.981869",
    "search_query": "ArriVent BioPharma, Inc.",
    "url": "https://clinicaltrials.gov/search?term=ArriVent+BioPharma,+Inc."
  }
}